Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Impax Laboratories has entered into a product development and supply agreement with New Jersey-based formulation and manufacturing company IGI Laboratories.
Subscribe to our email newsletter
IGI will be responsible for developing two topical drug products, obtaining FDA marketing approvals, and manufacturing the commercial products. Impax will market and distribute the products through Global Pharmaceuticals, its generics division.
IGI Laboratories is focused on the development and commercialization of products for the dermatology market.
Impax Laboratories is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products.
Charlie Moore, president and CEO of IGI, said: “IGI is proud to announce this partnership with a prestigious pharmaceutical company such as Impax. We hope this will lead to further opportunities for cooperation in the topical products arena.”
Chris Mengler, president of Global Pharmaceuticals, said: “We look forward to working with the experienced team at IGI Laboratories on these two topical drug products. This marks our initial entry into alternative dosage forms as we begin to execute our strategy of diversifying our product base.
“Our business development activities will continue to focus on delivering growth from high-value products, technologies, and businesses in complementary dosage forms.”